Filing Flows › Haemonetics (HAE) › Guidance & outlook
Haemonetics (HAE) guidance and outlook
Haemonetics' 10-Q filed Nov 5, 2026 makes 4 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- On October 8 2026, CSL announced that it expects to complete the rollout of Haemonetics’ devices and disposables under the supply agreement by the end of calendar year 2027, and CSL has informed us that it currently anticipates that the transition to Haemonetics devices and disposables will occur at all of CSL’s current U.S. plasma collection centers.
- • The potential that the expected strategic benefits and opportunities from completed or planned acquisitions, including our acquisitions of Vivasure, OpSens Inc. and Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”), divestitures or other strategic investments by us may not be realized or may take longer to realize than expected;
- • Our ability to obtain the anticipated benefits of restructuring programs that we have or may undertake, including our market and regional alignment initiative;
- • Our ability to execute and realize anticipated benefits from our investments in emerging economies;
Haemonetics' latest quarter
Haemonetics, Q2 FY27: revenue $358M (+9% year over year), operating margin 21.0%, net earnings $46.3M, operating cash flow $128M. The chart follows the revenue to costs, profit and cash.
Questions
What does Haemonetics expect?
On October 8 2026, CSL announced that it expects to complete the rollout of Haemonetics’ devices and disposables under the supply agreement by the end of calendar year 2027, and CSL has informed us that it currently anticipates that the transition to Haemonetics devices and disposables will occur at all of CSL’s current U.S. plasma collection centers. • The potential that the expected strategic benefits and opportunities from completed or planned acquisitions, including our acquisitions of Vivasure, OpSens Inc. and Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”), divest
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.